In most series of malignant tumors of the nasopharynx that have been reported (1, 3–8, 11–14, 16, 17), adenocarcinomas represent less than 5 per cent of the total number of cases. Despite the recognized high incidence of neoplasms of the nasopharynx among the Chinese and Indonesians (2, 8, 18) adenocarcinoma is almost unknown in these groups. The biologic behavior of adenocarcinoma in its response to irradiation varies from the more common histologic types of nasopharyngeal cancer. The disease frequently persists at the primary site, and the patients die of extension into the skull and brain. Radiation therapists must be aware of these differences and, hence, of the radiotherapeutic approach to the disease. From the evidence in the literature, adenocarcinoma of the nasopharynx is seldom cured (1, 3–8, 11–14, 16, 17). Cures have nevertheless been reported when the radiation dose is carried to a high level within the nasopharynx (10, 14, 15). A twelve-year survival after surgical removal has also been recor...